IAN Reviews in Neurology 2022: Epilepsy-Innovations and Advances PN Sylaja
INDEX
Page numbers followed by f refer to figure and t refer to table.
A
Ablation 161
hyperintense area of 166f
hypodense area of 166f
steps of 166f
Acalculia 5
Accelerometer 177
Acetazolamide 87
Acquired anterior opercular syndrome 108
Adrenocorticotropic hormone 14, 15, 71, 181
Age limited epilepsy syndrome 185
Aldehyde dehydrogenase 208
Alkyl carbamate 188
Alzheimer's disease 93
Ambulatory intracranial electroencephalogram 171
Amino acid change 80
Amygdala 121
Anesthesia, level of 50
Anesthetic
cycling and duration of 50
speed of weaning of 50
Anesthetic medications 4750
ketamine 50
midazolam 49
propofol 49
thiopental and pentobarbital 49
Aneuploidy 80
Angelman syndrome 81, 132, 191
Antiarrhythmic drugs 95
Antibiotic irrigation 129
Anti-CD20 monoclonal antibody 31
Antiepileptic drugs 20, 89
advantages of withdrawal 21
dose 88f
newer 64
third-generation 44
withdrawal of 20
Antiseizure medication 20, 21, 23, 30, 34f, 48, 49, 61, 64t, 65, 66, 74, 85, 89, 92, 93, 100, 115, 131, 185, 198, 206
armamentarium of 180
general strategies 29
mechanism of action of 30t
treatment lag of 68
Anxiety 61
phenomenology of 63t
Aphasia 5
Apnea 156
Appetite suppression 189
Arcuate fasciculus 111
Arrhythmia 93
Arterial blood gas analysis 58
Arterial strokes 24
Arteriovenous malformations 133
Artificial intelligence 149, 187, 192, 204, 209
Asymmetric tonic seizures, semiology of 145f
Asystole 66, 156
Atkins diet 32
Atonic seizures 74
Atrioventricular conduction defect 66
Auditory aura 153
Auras 152
nonspecific 154
type of 153
Autism 133
spectrum disorder 206
Autistic traits 135
Autoimmune
and inflammatory causes 202
and paraneoplastic causes 94
causes 200
encephalitis 25, 133
epilepsy 94, 133
thyroiditis 200
Autonomic aura 153
Autonomic manifestations 152, 155
Autonomic pharmacology 97
Axio rhizomelic atonia 108
B
Bacterial meningitis 197
Barbiturates 33, 201
Basal ganglia 148
Basic sciences
pathophysiology 13
recent advances in 13
Behavioral arrest 8
Behavioral disturbances 184
Behavioral problems 135
Behnke-Fried depth electrode 122
Benign familial
epilepsy syndromes 79
neonatal-infantile seizures 208
Benign Rolandic epilepsy 107
Benzodiazepines 30, 34, 47, 48, 5557, 134, 201
potency of 56
role of 190
Biotinidase deficiency 133, 136
Bispectral entropy 174
Bispectral squared entropy 174
Blindness 152
Blood–brain barrier 196f
level 53
Blood-oxygen-level-dependent effect 147
Body perception illusion 153, 154
Bone
disorders 65
flap size 163f
loss in epilepsy, 65t
marrow transplantation 64
mineral disorders 61
Bradycardia 156
Brain
in petri dish 191
neurotransmitters 97
organoids 187, 191
parenchyma 118, 121, 196
trauma 20, 24, 25
tumors 20, 24, 25, 62
Brainstem level 13
Breastfeeding 85, 90, 183
Brivaracetam 29, 30, 3335, 38, 43, 187, 188, 207
Buccal midazolam 213
Bupropion 201
Busulfan 64
C
Calcium 30
channel 208
Cancer 64
chemotherapeutic agents 64t
medications, high doses of 64
systemic 61
Cannabidiol 3336, 38, 39, 43, 188
adverse events 39
dosage 39
mechanism of action 39
Carbamazepine 2831, 34, 35, 41, 89, 90, 95, 96, 108, 115, 181, 183, 207
Cardiac arrhythmias 93
Cardiac disorders 66
Cardiac pacemaker 126
Cardiovascular and respiratory disorders 61
Cardiovascular defects 89
Cardiovascular issues 93
Carotid sinus syndrome 93
Catamenial epilepsy 85, 86
management of 86
types of 86f
Cavernoma 103
Cavernous angiomas 120
CDKL5 gene mutation 189
Cenobamate 30, 3336, 3840, 43, 188
Central hypotonia 135
Central nervous system 38, 125, 194
infections 197
Centrotemporal spikes 107, 108
Cerebellar atrophy 134
Cerebral
abscess 122
activation 103
disorder, acute 194
glucose consumption 104
hemorrhage 94
malaria 25, 197
palsy 21
physiology 148
toxoplasmosis 25
venous thrombosis 198
Cerebrospinal fluid 48
Cerebrovascular disorders 93
Channelopathies 132
Chapeau de gendarme 158
Childhood epilepsy 131
Chlorambucil 64
Chloride channel 208
Chlorpromazine 201
Chocking 156
Choreiform movement disorder 135
Chromosomal syndromes 132
Cingulate cortex 152
Cingulum 121
Citalopram 201
Clobazam 23, 36, 37, 87, 183, 207
Clonazepam 15, 23, 58, 64, 87
Clonic jerks, asymmetric ending of 159
Clozapine 201
Cluster analysis, type of 152
Cognitive 5t
decline 69, 70f, 110
deficits, postictal 159
disability 137
disturbances 151
dysfunction 69
functions 69t
impairment 104
manifestations 152, 155
regression 133
Combined oral contraceptive pill 87
Comparative genomic hybridization 78, 79, 206
Complex epilepsy 131
Connective tissue disorders 200
Consciousness
alteration of 152, 154
loss of 171
Contraception 85, 87
Convolutional neural network 174, 175
Coronary artery disease 66
Corpus callosotomy 105
Corpus callosum 163f
Cortical abnormalities 146
Cortical blindness 135
Cortical dysplasia 105, 164
Cortical malformations 148
Cortical stimulation 118
Corticosteroids 14, 15
Corticotrophin-releasing hormone 13
Craniotomy 163f
Creatine deficiency disorders 136
Creatinine 195
Cryptococcal meningitis 25, 197
Cryptogenic epilepsy 182
Cryptogenic supra-refractory status epilepticus, evidence in 51
Cyclophosphamide 64
CYP2C19 substrates 36
CYP3A4 substrates 36
Cytochrome P450 39
Cytogenetic studies 206
Cytotoxic agents 95
D
Deep brain stimulation 105, 125, 126, 128
Delalande's technique 162
Dementias 93
DEPDC5 gene mutation 83
Depression 61, 63
frequency of 63
phenomenology of 63t
Desmethylclobazam 36
Developmental and epileptic encephalopathy 133
Diazepam 55, 57, 58, 187
Diffusion tensor imaging 111, 143, 146, 205
Diphenhydramine 201
Disease-specific therapies 31
Doose syndrome 111
Down's syndrome-related epilepsy 132
Doxorubicin 64
Dravet syndrome 22, 39, 68, 70, 73, 79, 80, 133, 134, 137, 188, 208
Drowsy 164
Drug refractory epilepsy, cases of 204
Drug-resistant
epilepsy 2, 27, 28, 137, 161, 182, 189
focal epilepsy, case of 148f
idiopathic generalized epilepticus 9t, 182
Dyselectrolytemia 196
Dysembryoplastic neuroepithelial tumors 103, 105
Dyskinesias 134
Dysphasia 5
Dystonic limb posturing 157
Dystonic posturing 156
E
Early infantile epileptic encephalopathy 71, 133, 136
Early myoclonic encephalopathy 22, 79, 133
Early-onset epileptic encephalopathy 133
Echocardiogram monitoring 189
Eclampsia 196, 197, 201
Electrical shock 152
Electrical status epilepticus in sleep 109
Electrical stimulation 125
Electroconvulsive therapy 52
Electrocorticography 172
Electroencephalography 6, 9, 15, 74, 102, 109, 111, 115, 118, 145, 175, 181, 185, 192
abnormal 28
changes 78
in atonic drops 109f
in elderly epilepsy 94
role of 23
Electrolyte and metabolic disorders 200, 202
Emaptica 177
Emergency surgery 52
Emotional facial paresis 157
Encephalitis 197
Encephalopathic disorders 197
Encephalopathy 197
developmental 2
refractory 136
subacute 136
Endocrine impairment 168
Endoscopic corpus callosotomy 161, 162
Endoscopic disconnection 164
Endoscopic hemispherotomy 161, 162
technique of 162
Enzyme inducibility 97
Epi-care 178f
Epidiolex 188
Epigastric aura 152, 156
Epigenetics 191
Epihunter 176
Epilepsy 2, 93, 98, 125, 204
advances in genetics of 78
and pregnancy 88
classification of 132t
complex 131, 132
etiological classification of 6
genetics 27, 79
in elderly 92
in women 85
infantile migrating focal seizures 79
management 92, 96, 101
multifocal 133
natural history of 27, 180
poststroke 20, 24, 25
precision medicine in 209f
prognosis of 181, 182
surgery 20, 100, 101, 118, 146, 180
Epilepsy syndromes 2, 8, 22, 22t, 133, 180, 206, 208
and genes involved 79t
diagnosis 6f
prognosis 181
Epileptic auras, significance 153t
Epileptic disorders 136
Epileptic encephalopathy 2, 68, 70t, 77f, 78, 80, 131
Epileptic nystagmus 157
Epileptic seizures 171
Epileptic spasms 5, 12, 74
in cluster 68
treatment of 14
Epileptic syndromes 70, 73, 134
Epileptic zone 118
Epileptiform discharges 166f
Epileptogenesis, development of 31
Epileptogenic foci 103t
Epileptogenic lesions 105
Epileptogenic network 22
Epileptogenic zone 143
Epileptogenicity, hallmark of 148
Epileptologists 210
Eslicarbazepine 30, 33, 35, 38, 40, 41, 95
acetate 34, 35, 43
adverse effects 41
dosing 41
mechanism of action 40
Estradiol 85
Estrogen 85
Ethosuximide 31, 33, 34, 87, 181
Everolimus 189
Exacerbate seizures 28
Eye blinking 157
bilateral 157
unilateral 157
F
Facial dysmorphisms 204
Febrile infection-related epilepsy syndrome 31, 70, 133, 137
Febrile seizures 134, 182
Felbamate 30, 31
Fencing posture 158
Fenfluramine 189
Fertility 87
Figure-of-4 sign 158
Fluorescence in situ hybridization 78, 81, 83
Focal cortical dysplasia 103, 122, 146, 210
Focal electrographic seizure 102f
Focal epilepsy
presurgical workup of 102f
syndromes 83, 131
Focal seizures 139f, 156
Folic acid 87
Forced thinking 153, 154
Fosphenytoin 47, 59
Fourier transform
fast 192
short-term 175
Fractional anisotropy 205
Fragile X
epilepsy 132
syndrome 81
Freiburg database 174
Frequent refractory seizures 108
Frontal lobe epilepsy 156, 212
Frontotemporal dementia 94
Fusobacterium 191
G
Gabapentin 29, 30, 31, 34, 87, 183, 208
GABA-related actions 30
Gamma knife in epilepsy surgery 164, 168
Gamma-aminobutyric acid 30, 48, 85, 200
Ganaxolone 137
Ganglioglioma 103
Gate theory 126
Gene therapy 78
Gene-modifying techniques 187
Genetic abnormalities 205
Genetic analysis techniques 80
Genetic counseling 82
Genetic epilepsy 132, 182
Genetic generalized epilepsies 8
Genetic influences
complex interplay of 196f
in drug metabolism 206f
in drug transporters 206
in ion channels 207
of ADRS–HLA 207t
of adverse drug reactions 206
of ion channels 208t
Genetic mutations 137
Genetic testing
and coverage range 81t
in epilepsy 83
Genetic underpinnings 62
Genetic variants 80, 83
Genotype-phenotype relationship 79
Geriatric autoimmune disorders 94
Geriatric neurology 92
Glasgow Coma Scale scores 95
Gliosis 94
post-traumatic 103
Glucose transporter 208
type 1 15, 133, 136
Glutamate 30
Glutamate decarboxylase 65 48, 94
antibody 48
Glutamatergic transmission 85
blockade of 30
Goosebumps 156
Granuloma 94
GRIN2A mutations 137
Gustatory aura 153, 154
Gut-brain axis 187, 191
Gut microbiome 191
H
Habitual seizure 122
Hallucinations 152
Head and eye version 158
Head trauma 197
Heart disease, structural 93
Hemiconvulsion-hemiplegia-epilepsy 70
Hemispherectomy 162
Hemispherotomy 161
Hemogram, complete 58
Hemorrhagic stroke 198
Hepatic and renal diseases 200
Hepatic enzymes 64
Hepatic metabolism 97
Herpes encephalitis 24
Herpes simplex
encephalitis 97f, 133
virus 197
Heschl's gyrus 153
Heterotopias 120
Hippocampal changes 146
Hippocampal excitatory neurons 192
Hippocampal sclerosis 103, 133, 182, 210
Histone lysine deacetylases 191
Histone modification 80
Homoeostatic mechanisms 97
Hormonal contraceptives 36, 37
Human brain organoids derived 191
Human immunodeficiency virus 25
Human leukocyte antigen 206, 207
Human pluripotent stem cells 191
Hydantoins 33
Hydrocephalus 189
Hydrocortisone 15
Hygroma 184
Hyperactivity disorder 108
Hyperexcitable neuronal membranes 41
Hyperkinetic behavior 69
Hypermotor behavior 152
Hypertensive encephalopathy 196
Hyperventilation 156
Hypnic jerks 93t
Hypoglycemia 57
related injury 13
Hyponatremia 95, 194
Hypoperfusion 103
Hypotension 66
Hypothalamic hamartoma 133, 164, 166f
surgical procedures 165t
Hypothermia 52
role of 52
Hypotonia 134
Hypoventilation 156
Hypoxia, acute 195
Hypoxic encephalopathy 201, 202
Hypoxic-ischemic
encephalopathy 7
injury 196
Hypsarrhythmia 68, 71
I
Iatrogenic injury 148
Ictal 9, 63, 103
activity 47, 48
autonomic manifestations 156t
bradycardia 66
grasping 157
gyration 158
nystagmus 158
piloerection 157
pouting 158
speech 157, 158
spitting and vomiting 158
Ictogenesis 172
Ideal rescue therapy agent 213
Idiopathic generalized epilepsy syndromes, prognosis of 182
Idiosyncratic reactions 97
Ifosfamide 64
Immune epilepsies 133
Immune-mediated epilepsies 136
Immunodeficiency disorders, primary 132
Immunomodulatory agents 51
Inborn errors of
creatine metabolism 133
metabolism 80
Infantile epilepsies 80
Infantile epileptic spasms syndrome 12, 68, 70, 71
structural etiologies of 13f
Infantile spasms 12, 71, 134
syndrome 79
Infantile-onset epilepsy 80
Infections 24
Infectious epilepsies 133
Inflammation 194
role of 31
Inhalational halogenated anesthetics 50
Inherited metabolic disorder 136
Instability, postural 93
Intellectual disability 132, 133, 206
Intelligence quotient 68, 115, 128
Interictal 63
abnormalities 185
discharges 148
electroencephalogram 68, 70f, 73f
epileptiform discharge 111, 147
Interleukin 1-beta 31
Interleukin 6 31
Intracarotid amobarbital procedure 147
Intracerebral hemorrhage 122, 198
Intracranial electroencephalogram 174, 175
Intracranial hemorrhage 198
Intractable epilepsy 149
Intractable focal epilepsy, case of 145f
Intramuscular adrenocorticotropic hormone 14
Intranasal diazepam 190, 213
Intranasal midazolam 187, 190, 213
Intravenous immunoglobulin 49, 51, 114, 115
Intravenous methylprednisolone 49, 115
Ipsilateral hemisphere 157
Irinotecan 64
Irritability 69
Ischemic infarcts 94
Ischemic stroke 195, 198
Isoflurane 208
Ivabradine 208
J
Jacksonian march 152, 153
Janus kinase-signal transducer pathway 136
Juvenile myoclonic epilepsy 22, 180, 181
K
Karyotyping 78, 80
Katamenios 86
KCNQ2 gene 134
KCNQ2-related epilepsies 134
KCNT1 channel-related epilepsy 137
KCNT1 gene 135
Ketamine 48, 208
Ketogenic diet 15, 27, 52, 134
role of 32
L
Lacosamide 30, 31, 3335, 37, 38, 40, 41, 43, 59, 64
adverse events 42
dosing 42
Lamberink predictive model 22
Lamotrigine 29, 30, 31, 34, 36, 87, 89, 114, 183, 207, 208
Landau–Kleffner syndrome 73, 79, 113f, 108, 137, 181
Language lateralization 148
Laser interstitial
ablation 164
thermal
ablation 120
therapy 164, 187, 190
thermotherapy 161
Lead malfunction 122
Lennox–Gastaut syndrome 6, 22, 21, 28, 39, 70, 74, 79, 134, 161, 162, 181, 188, 189
atypical absences of 111
Lesionectomy 105
Lethargy 189
Levetiracetam 2931, 34, 35, 47, 55, 59, 64, 65, 87, 90, 89, 95, 114, 134, 181, 183, 201
Limb movements, paucity of 157
Lissencephaly 13f
Liver function tests 58
Lorazepam 55, 57, 58, 64
M
Magnesium 53
Magnetoencephalography 28, 111, 144
Medically intractable focal epilepsy 145f, 147f
Medically refractory epilepsy 118
Mefenamic acid 201
Memantine 208
Memory
deficits 147
impairment 5
long short-term 175
Mendelian inheritance 79, 131
Meningitis 122
Meningocele 184
Meningoencephalocele 103
Mental deterioration 68
Mental retardation 21
Mephobarbital 33
Mesial temporal
lobe epilepsies 180
sclerosis 103, 122, 168
structures 123f
Metabolic defect in epileptic child 136t
Metabolic disorders 197
Metabolic epilepsy 133, 136
Methotrexate 64
Methylprednisolone pulse therapy 74, 74f
Microbiome in epilepsy 191
Midazolam 48, 55, 57, 58
Migraine 61, 62, 65
risk of 65
Migrating focal seizures 138
epilepsy of infancy with 70
Migrating partial seizures of infancy 22
Miosis 156
Mitochondrial encephalopathies 182
Monosomy 80
Mood disorders, treatment of 64
Mood stabilization 69
Morphometry
analysis program 146
surface-based 146
voxel-based 146, 210
Mortality implications 62
Motor function 104
Motor manifestations 152, 154
Movement disorder 133, 135
Mydriasis 156
Myoclonic absence 5
epilepsy 22
Myoclonic atonic epilepsy 111
Myoclonic epilepsy
in infancy, severe 73
progressive 70, 80
Myoclonic seizures 73, 74, 136
Myoclonic-astatic epilepsy 134
Myoclonic-tonic-clonic 5
N
Narcolepsy 93
Nasopharyngeal airway 56
Natalizumab 31
Neonatal seizures and epilepsies, classification of 7
Neurocritical Care Society 47
Neurocutaneous markers 204
Neurocutaneous syndromes 133
Neurodegenerative processes 93
Neurodevelopmental regression, severe 135
Neuroimaging in elderly epilepsy 94
Neuroinfections 92
Neuroinflammation 27
Neurological comorbidity 62
Neurological disorder 132
Neurological examination 109, 182
Neurological signs 135
Neurological symptoms 137
Neuromodulation 125
in epilepsy 125
Neuropsychology 100, 104
Neurosteroids 189
Neurostimulation devices 126t
Neurostimulation in epilepsy, modern day 125
Neurostimulation techniques 180
Neurotransmitter release, modulation of 30
Next-generation sequencing techniques 82
Nightwatch 177f, 178
Nitrazepam 15
Nondominant hemisphere 157
Nonforced head deviation 157
Noninvasive neuromodulation technique 190
Novel medical technology 191
Nucleotide repeat expansions 78, 80
Nullisomy 80
O
Ohtahara syndrome 22, 71, 79, 133
Olfactory aura 153, 154
Oral benzodiazepines 213
Organ dysfunction 200
Oromotor dysfunction 108
Orphan disease 132
Orthostatic hypotension 93
Osteoporosis, risk for 95
Oxazolidinediones 33
Oxcarbamepine 207
Oxcarbazepine 2931, 34, 89, 90, 114, 115, 181, 183
P
Paclitaxel 64
Palliative neurosurgical procedures 101
Panayiotopoulos syndrome 180
Paralytic ileus, risk of 53
Paraneoplastic encephalitis antibody panel 58
Parkinson's disease 62
Paroxysmal nonepileptic seizures 28
Peak plasma concentration 214
Pediatric epilepsy surgery 24
Pediatric rare epilepsy syndromes 131
Perampanel 29, 30, 31, 3335, 37, 38, 40, 41, 44
Peri-ictal
nose-wiping 158
water drinking 158
Perimenstrual seizure cluster 86
Perinatal birth injuries 13
Perioral cyanosis 133
Periventricular nodular heterotopia 148
Phenobarbitone 29, 30, 31, 59, 181, 185, 207
Phenytoin 2831, 3436, 55, 59, 89, 207
Photoparoxysmal response 185
Photoplethysmogram 177
Photosensitive seizures 73
Physics 126
closed versus open loop 126
fundamentals 126
Piloerection 156
Placebo group 189
Plasma exchange 49
Polymicrogyria, detections of 146
Polypharmacy and interactions 97
Post epilepsy surgery 24, 24f
Posterior reversible encephalopathy syndrome 24, 201, 202
Potassium 30
actions 30
channel 208
gene 192
Potential epileptogenic foci 102
Potentiation 30
Prader–Willi syndrome 81
Precision medicine 78, 82, 204
Prednisolone 15
Prednisone 15
Pregabalin 30, 34, 87
Prehospital
management 55
pharmacological treatment 57
treatment of status epilepticus trial 57
Preictal and postictal psychiatric ailments 63
Preictal headache 153
Primidone 33, 34
Progesterone 85
Progressive multifocal leukoencephalopathy 25
Progressive neurological deterioration 70t
Progressive organic dysfunction 196
Propofol 48, 208
Protein binding 97
Proteobacterium in healthy controls 191
Pseudo-Lennox syndrome 73
Pseudo-refractoriness, concept of 28
Pseudoresistance 182
Psychiatric
ailments 64
comorbidity 62, 63, 104
disorders 63, 110
function 69
problems 132
symptom 69
Psychomotor regression 110
Psychosis 61
in epilepsy, phenomenology of 63t
Pyridoxine 15, 53
dependent epilepsy 133, 136, 208
supplementation 208
Pyruvate dehydrogenase 136
Q
Quality of life 94
Quetiapine 201
Quinidine 134
R
Radiofrequency 146, 161
ablation 161
electrodes 161
Rapamycin 189
mechanistic target of 83
Rasmussen syndrome 70
Rasmussen's encephalitis 22, 133, 137, 184
post-stroke atrophy 162
Rational polytherapy 27, 31
Rectal diazepam 213
Recurrent neural networks 174
Refractoriness, define 47
Refractory epilepsy 131
treatment of 187
Refractory status epilepticus 51, 47
Renal elimination 97
Renal failure, chronic 196
Renal function tests 58
Rescue therapy 211, 214
formulations 213
in epilepsy 211
indications for 212
Resective epilepsy surgery 84t
Residual gliotic scars 24
Respiratory distress, case of 56
Responsive neurostimulation 125, 126, 127, 161, 167, 167f, 171, 190
complications 128
long-term outcomes 128
Restless legs syndrome 93
Retigabine 30, 31
Rett syndrome 191
Rhythmic ictal nonclonic hand motions 156, 157
Rifampicin 35
Right parieto-occipital cavernoma 199f
Rituximab 31
Robot-assisted procedure 122
Robot-assisted stereoelectroencephalography electrode insertion 122
Robotic-guided hypothalamic hamartoma ablation 164
Robotic thermocoagulative hemispherotomy 163
development of 161
Rolandic epilepsy 22, 181, 185
cases of 180
Rolandic status epilepticus 108
Rufinamide 30, 3335, 37, 38, 42, 44
S
Salivation 156
Sanger sequencing 79
Scar epilepsy 20
Sclerosis, multiple 62
SCN2A related epilepsies 134
Scout image 121f
Seizures 61, 109
classification 1, 3
cluster 211, 212, 214
despite treatment 22
detection devices for diagnosis 176
during pregnancy 88
epileptic 2
focal 2
freedom 183f
frequency 204
generation 148, 172
nature of 95
risk of recurrence after first unprovoked 181
self-reporting 176
semiological manifestations of 152
semiology 139, 151, 152, 205
spread of 122
types, multiple 22
Semiology, postictal 8
Sensor dot 176
Sensorimotor area 152
Sensory auras, contralateral or bilateral 152
Sensory seizures 93
Serine-threonine kinase 135
Serum
calcium 195
electrolytes 58
glucose 195
magnesium 195
sodium 195
Simple motor manifestations 154
Single nucleotide variants 78, 80, 81
Sleep
apnea 93
disorders 93
disturbances 17
Sodium 30
Somatic comorbidity 62
Somatognosia 153
Somatosensory auras 152
Somnolence 189
Spasms
control of 16
prevention of development of 17t
Spastic quadriparesis 134, 135
SPEAC device 177, 177f
Specific epilepsy syndromes, etiology 8
Specific genetic syndrome 133
Specific lateralizing signs 156
Spinal cord stimulator device 126
Spinocerebellar ataxias 62
Sporadic hemiplegic migraine 65
Status epilepticus 55, 92
Stem cells 191
Stereoelectroencephalography 118, 119, 120, 120t, 122, 162
complications 122
technique of 168f
Stereotactic radiofrequency thermocoagulation 164
electrode, placement of 166f
Stereotactic radiosurgery 168
Stereotaxy 121
Steroid 95
responsive encephalopathy 200
Steven–Johnson syndrome 41, 206, 207
Stiripentol 3335, 37, 38, 42, 44, 134
Stroke 93, 196
acute 197, 198
incidence of 197
subtypes 198
STXBP1 mutation 71, 73f
Subarachnoid hemorrhage 198
Subcortical flair hyperintensity 198f
Subcortical structures 146
Subdural electrodes 119, 120t
Subdural hematoma, post-traumatic left convexity 199f
Subependymal giant cell astrocytomas 189
Submillimeter range 144
Succinimides 33
Sudden unexpected death in epilepsy 16, 21, 29, 100, 171, 182, 212
Super-refractory status epilepticus 47
Surface electromyography signals 177
Sweating 156
Symptomatic seizure, acute 24, 95, 194, 195
alcohol-related 201
causes 194
common metabolic disorders 195t
epidemiology of 196
etiology of 197
frequency of 197, 198, 199, 200
in elderly 92
list of drugs and toxins 201t
risk factors of 198, 199, 200
treatment of 198, 199, 200
Synaptic transmission, coregulator of 208
Synthetic minority oversampling technique 174
Systemic lupus erythematosus 200
T
Tachycardia 156
Tamoxifen 64
Tandem mass spectrometry 83
Targeted genetic testing, diagnosis 205
Technology, improvement of 187
Temporal lobe epilepsy 101, 149, 156, 190, 191
Temporal lobectomy, anterior 168
Temporal plus epilepsy 120
Teniposide 64
Tetracosactide 15
Tetrasomy 80
Thalamus 146, 148
anterior nucleus of 128
for epilepsy 128, 129f
Theophylline 95
Thiopentone 48
Thiotepa 64
Thrombocytopenia, cause 64
Thyrotoxicosis 93
Tiagabine 30
Timothy syndrome 191
Tocilizumab 31
Todd's palsy 157
Todd's paralysis 159, 199
Tongue bite, unilateral 159
Tonic head version 157
Tonic-clonic seizures 94f
Topiramate 15, 2931, 34, 65, 87, 89, 90, 183
Topotecan 64
Toxic epidermal necrolysis 41, 206, 207
Tractography 184
Tramadol 201
Transaminase elevation 189
Transaminitis 189
Transcranial direct current stimulation 190
Transcranial magnetic stimulation, repetitive 52
Transient ischemic attack 93
Traumatic brain injury 195, 199, 202
Trimethadione 33
Tuberculoma 20, 25
Tuberous sclerosis 120, 191
complex 13f, 39, 189
Tumor necrosis factor-alpha 31
U
Unprovoked seizure 194
Urea nitrogen 195
Urinary urge 156
V
Vaccine-related encephalopathy 134
Vagal nerve stimulation 162, 190
implantation 102
Vagus nerve stimulation 125, 126, 128
complications 127
long-term outcomes 127
Valproate 29, 30, 31, 34, 36, 47, 55, 59, 65, 89, 95, 207
monotherapy 89
Valproic acid 90, 115
Vascular cognitive impairment 94
Vascular endothelial permeability 196
Vasovagal syncope 93
Venlafaxine 201
Verapamil 53
Vertiginous aura 153
Video-electroencephalography 101, 169f
monitoring 102, 119f, 151
semiology 152t
Vigabatrin 15, 30, 31, 71
and combined therapy 15
Vincristine 64
Visual aura 152
unilateral complex 153
various forms of 153
Vitamin D supplements 95
Voltage-dependent sodium channels 41
Voltage-gated
ion channels 30, 208
potassium channel 208
sodium channel 137
W
Wada testing 104
Warfarin 95
Wearable seizure detection devices 177
West syndrome 12, 21, 68, 71, 73, 79, 133, 137, 180
White matter fraction maps 148
Whole-exome sequencing 78, 81, 82, 206
Whole-genome sequencing 78, 79, 81, 82, 83, 206
Wound hygiene 129
X
X chromosome 135
X-linked disorder 135
Z
Zonisamide 15, 29, 30, 31, 87, 90, 183, 207
×
Chapter Notes

Save Clear


New Seizure and Epilepsy Classifications: Current and Future PerspectivesCHAPTER 1

Aparajita Chatterjee,
Kurupath Radhakrishnan

ABSTRACT

Classifications that are universally adopted and practiced provide a common language facilitating communication among clinicians, researchers, and students, and are therefore extremely useful. In the last few years, the International League Against Epilepsy (ILAE) has published new classification schemes for seizures and epilepsies in general, and a focused classification for seizures and epilepsy in the neonates. A new set of position papers have also been published this year, aimed to define the various epilepsy syndromes. In this review, we discuss in detail the current classifications of seizures and epilepsies, and their merits and shortcomings. We have also touched upon the classification of seizures and epilepsies in the neonates. These new classifications have allowed for the inclusion of some previously unclassifiable seizure types and epilepsies and have utilized more intuitive terminology. Nonetheless, they fall short in several aspects and have introduced new ambiguities, highlighting the need for incessant refinements and revisions. The rapid advances in genomics and brain connectomics will play pivotal roles in future classifications. The ultimate goal of classification systems in people with epilepsy should be to facilitate the practice of precision medicine by enabling the choice of personalized diagnostic and therapeutic strategies.
Keywords: Classification, Epilepsy, Etiology, Focal, Generalized, Seizures
Learn from yesterday, live for today, hope for tomorrow.
The important thing is not to stop questioning.
—Albert Einstein
 
INTRODUCTION
Classification has been commonly applied since antiquity by mankind to simplify approach to various aspects of life. It is something we deal with in everyday life and can range from the most basic to the most complex. To classify is to put like with like and separate the disparate from each other. One might wonder why we need these systems in the first place. Confucius in 6th century before Christian era (BCE) remarked “If names are not correct, language is not in accordance with the truth of things. If language is not in accordance with the truth of things, affairs cannot be carried on to success.”1 Simply put, classification systems help us in conveying relevant information, which is far more than what individual entities otherwise would. Classification systems are invaluable in the field of epilepsy in order to communicate the diagnosis, prognosis, and possible therapeutic approaches to fellow clinicians and researchers, and also to people with epilepsy and their caregivers.
The diagnosis of epilepsy is primarily clinical, based on the detailed information gathered by history taking from the patient and from those who have witnessed the event. Investigations such as electroencephalogram (EEG), magnetic resonance imaging (MRI), and others can only support and further refine the clinical diagnosis but cannot be a substitute to history. We strongly recommend routine use the five axes diagnostic scheme proposed by the International League Against Epilepsy (ILAE)2 (Fig. 1) in order to be comprehensive in our diagnostic approach and to minimize the misdiagnosis, and to facilitate classification of seizure type, epilepsy type, epilepsy syndrome, and its consequences on the patient's quality of life.
In this review, firstly, we will discuss the new classification systems proposed by the ILAE on seizures and epilepsies 2by tracing the evolution from the past to the present, and by underscoring why periodic changes in classification were necessitated. We will also briefly touch upon the new ILAE classifications on neonatal seizures and epilepsies. The review does not address the classification of epilepsy emergencies such as status epilepticus. Secondly, we shall debate on the merits and limitations of the present ILAE classifications. Lastly, we will speculate on how the present rapid advances in brain structural and functional imaging, connectomics, and genomics will give rise to future epilepsy classification systems aimed at achieving precision in the diagnosis and treatment.
The foundation slab to any classification is to have clear definitions of whatever is being classified. In Table 1, we have provided the current ILAE definitions for seizures, epilepsies and epilepsy syndromes, and other related terms.
 
EVOLUTION OF CLASSIFICATION: PAST TO PRESENT
 
Historical Perspectives
Man, from times immemorial, has been aware of different types of seizures and epilepsies. Well ahead of the Western civilization, our ancient Ayurveda (around 5,000 years BCE) recognized that seizures occur due to a disturbance in brain function or flow of “humors” to the brain.3
zoom view
Fig. 1: The five axes diagnostic schemes for people with seizures and epilepsies.
TABLE 1   Definitions proposed by the International League Against Epilepsy.
Terminology
Definition
Reference
Epileptic seizure
Epileptic seizure is defined as a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain
8,9
Generalized seizure
Generalized seizures are those originating at some point within, and rapidly engaging, bilaterally distributed networks
Focal seizure
Focal seizures are those originating within networks limited to one hemisphere
Epilepsy
Epilepsy is a pathologic and enduring tendency to have recurrent seizures. It is diagnosed when an individual has one of the following: at least two unprovoked or reflex seizures >24 hours apart, or one unprovoked or reflex seizure and a probability of having another seizure similar to the general recurrence risk after two unprovoked seizures (≥60%) over the next 10 years, or an epilepsy syndrome
11
Epilepsy syndrome
Epilepsy syndrome is defined as a characteristic cluster of clinical and electroencephalogram (EEG) features, often supported by specific etiological findings (structural, genetic, metabolic, immune, and infectious). The diagnosis of a syndrome in an individual with epilepsy frequently carries prognostic and treatment implications. Syndromes often have age-dependent presentations and a range of specific comorbidities
14,17
Epilepsy resolved
Epilepsy is considered to be “resolved” for individuals who either had an age-dependent epilepsy syndrome but are now past the applicable age or those who have remained seizure-free for the last 10 years, with no use of antiseizure medications for the last 5 years
11
Drug-resistant epilepsy
Drug-resistant epilepsy is defined as failure of adequate trials of two tolerated and appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom. A person is supposed to have achieved “sustained seizure freedom” when free of seizures for a minimum period of 12 months or for a period three times the previous longest seizure-free period, whichever is longer
15
Epileptic encephalopathy
Epileptic encephalopathy is defined as a condition in which epileptiform abnormalities are believed to contribute to the progressive disturbance in cerebral function
14
Developmental encephalopathy
Developmental encephalopathy is defined as a condition where there is just developmental impairment without frequent epileptic activity associated with regression or further slowing of development
14
Developmental and epileptic encephalopathy
Defined as a condition where both epileptic activity and preexisting developmental delay coexist, and contribute to further deterioration of cognitive development, most commonly due to underlying genetic mutation
14
3Ayurveda texts of those times have described classifications of seizures with clear descriptions of generalized tonic-clonic seizures, focal seizures with impaired awareness and secondarily generalized seizures.3 There was also an understanding that different causes for seizures and epilepsy existed, including post-traumatic epilepsy.3 A Babylonian tablet dating back to 1067–1046 BCE, contained descriptions about different types of seizures.4 Galenus proposed two different types of epilepsies—“idiopathic” epilepsy when the disorder was primarily due to a malfunctioning of the brain, and “sympathetic” when it was due to secondary causes affecting the brain. The word “sympathetic” was later replaced by “symptomatic”.4 The first modern classification of epileptic seizures was proposed by Henri Gastaut in 1964, and its use became popular in the 1970s.5
The ILAE modernized the classification on epileptic seizures for the first time in 1981, which was prompted by the availability of video electroencephalography (VEEG).6 The 1981 ILAE Seizure Classification used terms such as “simple partial”, “complex partial”, “generalized”, and “unclassifiable” that have been in use until recently.6 The ILAE Classification of the Epilepsies and Epilepsy Syndromes were updated in 1989.7 A revision of the existing systems of classifications was proposed in the early 21st century, which led to a series of extensive discussions culminating the present day ILAE definitions and classifications of epileptic seizures and epilepsies.2,814 The ILAE Commission on Therapeutic Strategies provided a comprehensive definition of drug-resistant epilepsy in 2010.15 A new classification of neonatal seizures and epilepsy, which incorporated the directions given by the 2017 classification, was published in 2021.16 More recently, the Nosology and Definitions Task Force of the ILAE, has published a series of articles providing detailed definitions of epilepsy syndromes encompassing all age groups.1721 We have traced the chronological evolution of ILAE seizure and epilepsy classifications in Figure 2.
 
Need for Classifications and their Revisions
Since classifying seizures and epilepsies is a daunting task which necessitates in-depth deliberations on the part of the panel of epileptologists deputed to complete the job, and requires intensive efforts to familiarize new terminologies to clinicians in their practice of epileptology, one must wonder why we need these classifications. Jerome Engel, while deliberating about the classification systems, aptly stated: “The classification provided a universal vocabulary that not only facilitated communication among clinicians, but also established a taxonomic foundation for performing quantitative clinical and basic research on epilepsy”.2 For clinicians (general physicians, pediatricians, neurologists, epileptologists, and psychiatrists) and the patient's caregivers, the classifications enhance communication and discussion. From a research standpoint, having the classifications enables evaluation of the clinical courses of various epilepsy syndromes and in assembling a uniform cohort of patients to assess different pharmacological and nonpharmacological therapeutic strategies.
When we already have a user-friendly classification system in place, one might question the need to revise it periodically. The straightforward answers are that previous systems have had some major lacunae which needed to be remedied, and the advances which have happened in the field of epileptology in the recent years necessitated the revisions. With our mounting knowledge of genetics and inputs from neuroimaging, invasive EEG monitoring, brain connectomes, molecular biology, and new avenues in epilepsy therapeutics, need for an updated classification system which incorporated this newfound information became essential.
zoom view
Fig. 2: Historical landmarks on the development of the International League Against Epilepsy (ILAE) seizure and epilepsy classifications.
4The new ILAE definitions and classifications, when compared to the older ones, utilize alternative terms and contain several important additions. In general, these changes have enhanced user-friendliness, transparency, and versatility of the classifications, and allowed for inclusion of previously unclassifiable seizure and epilepsy types.
 
THE NEW INTERNATIONAL LEAGUE AGAINST EPILEPSY SEIZURE CLASSIFICATION
 
Rationale of Seizure Classification
Seizures can be classified on the basis of different characteristics and in many different ways. Previous classifications were largely based on anatomy as temporal, frontal, parietal, occipital, diencephalic, or brainstem seizures. At present, epilepsy is considered a network disease.22 From a network perspective, seizures arise from a point or points in neocortical, thalamocortical, limbic, and brainstem networks, and their semiology depend upon the propagation along preferential networks. Accordingly, while generalized epileptic seizures are conceptualized as originating at some point within, and rapidly engaging bilaterally distributed networks, focal epileptic seizures are conceptualized as originating within networks limited to one hemisphere (Table 1). Although our understanding of seizure networks is evolving rapidly, it is not yet sufficient enough to serve as a singular basis for seizure classification. The ILAE Task Force chose to refer to their new seizure classification as an “operational”, since at present it is not possible to have a comprehensive scientific classification where all seizure types find a place.12,13
 
Two Versions of the Seizure Classification
The new classification has a basic and expanded version, depending upon the needs and expertise of the individual using the classification (Figs. 3A and B).12,13 While the basic version will serve the requirement of physicians, pediatricians, general neurologists, nurses, and healthcare workers, the expanded version will be essential for epileptologists and researchers.
The epileptic seizures are categorized according to onset into focal, generalized, unknown, or unclassifiable. The term “focal” replaced the old term “partial” as it was felt to be too ambiguous and often conveys different meanings such as part of a seizure and without losing consciousness. The term “generalized” has been retained unchanged from the old classifications.
zoom view
Figs. 3A and B: The International League Against Epilepsy (ILAE) 2017 seizure classification. (A) Basic version; (B) Expanded version.
5A generalized onset seizure is one in which both the hemispheres are activated at the onset of the seizure according to the seizure semiology and EEG findings. “Unknown” onset refers to seizures where the onset is ambiguous, but other clinical manifestations are known. “Unclassified” remains as a category to start with, but a majority from this category will become classifiable with information added during follow-up visits by repeated history taking and review of smart phone recorded seizures. Focal seizures are classified as “aware” or “impaired awareness” seizures. These terms replace the older terminologies “simple” and “complex”, respectively. It should be emphasized that “impaired awareness” and “loss of consciousness” are not synonymous. If awareness is impaired at any time during a focal seizure, it should be classified as “focal seizure with impaired awareness”. In the basic version, the next step after consideration of the level of awareness for a focal seizure entails defining the onset as “motor” or “nonmotor”. Secondarily generalized seizures are now called “focal to bilateral tonic-clonic seizures”, in order to restrict “generalized” to seizures of generalized onset. When classifying generalized seizures, “aware” versus “impaired awareness” is omitted, since awareness is impaired in nearly all generalized seizures. Generalized motor seizures can further be classified as “tonic-clonic” or “other motor”. The nature of seizure onset is crucial, and a seizure whose onset was unwitnessed, followed by tonic-clonic activity should be labeled an “unknown onset to bilateral tonic-clonic seizure”.
The expanded classification (Fig. 3B) builds on the basic classification by enlarging the “motor” and “nonmotor” categories under all three types of seizure onsets (focal, generalized, and unknown). A focal motor seizure is classified by first determining whether awareness is impaired during any part of the seizure, thereby rendering it a focal impaired awareness seizure. The next level of classifier derives from the first sign or symptom of the seizure, even if not the ultimately most prominent sign or symptom, because the first symptom marks the seizure focus or network. After seizure categorization, expanded classification allows use of additional terms, either from the seizure classification, or from a suggested list of seizure descriptors (Table 2). We have summarized in Table 3 the major changes built-in to the new ILAE seizure classification when compared to previous classifications.
 
THE NEW INTERNATIONAL LEAGUE AGAINST EPILEPSY CLASSIFICATION
The ILAE position paper by Scheffer and colleagues provided a new classification of the epilepsies with a major thrust on the etiology at each step of the diagnostic process.14 After classification of seizure type, the clinician should aim to identify the patient's epilepsy type and where possible, the epilepsy syndrome.
TABLE 2   Common descriptors of behaviors during and after seizures.
Cognitive
  • Acalculia
  • Aphasia
  • Déjà vu
  • Jamais vu
  • Attention impairment
  • Dysphasia
  • Memory impairment
  • Neglect
Automatisms
  • Aggression
  • Eye blinking
  • Head nodding
  • Manual
  • Orofacial
  • Pedaling
  • Pelvic thrusting
  • Perseveration
  • Vocalization
Emotional or affective
  • Anxiety
  • Anger/agitation
  • Laughing (gelastic)
  • Crying (dacrystic)
  • Fear
  • Pleasure
  • Paranoia
Motor
  • Dysarthria
  • Dystonia
  • Fencer's posture figure-of-4
  • Jacksonian march
  • Incoordination
  • Paresis
  • Versive
Autonomic
  • Asystole
  • Bradycardia
  • Flushing
  • Gastrointestinal
  • Nausea
  • Pallor
  • Palpitations
  • Piloerection
  • Respiratory changes
Sensory
  • Auditory
  • Gustatory
  • Hot or cold sensations
  • Olfactory
  • Somatosensory
  • Vestibular
  • Visual
Laterality
  • Left
  • Right
  • Bilateral
TABLE 3   Summary of the major changes in terminologies and descriptions from 1981 to 2017 International League Against Epilepsy (ILAE) seizure classifications.
  • Change from “partial” to “focal” seizures
  • Seizure types can be either focal, generalized, or of unknown onset
  • Seizures of unknown onset may have features that can still be classified
  • Awareness is used as a classifier of focal seizures
  • The terms dyscognitive, simple partial, complex partial, psychic, and secondarily generalized have been removed from the current classification
  • New focal seizure types include automatisms, autonomic, behavior arrest, cognitive, emotional, hyperkinetic, sensory, and focal to bilateral tonic–clonic seizures (previously secondarily generalized seizures)
  • Atonic, clonic, epileptic spasms, myoclonic, and tonic seizures can be either focal or generalized
  • New generalized seizure types include absence with eyelid myoclonia, myoclonic absence, myoclonic–tonic–clonic, myoclonic–atonic, and epileptic spasms
  • Recurrent unprovoked epileptic seizures (epilepsy) were redefined as a “disease” and not a “disorder”
6
zoom view
Fig. 4: The International League Against Epilepsy (ILAE) 2017 classification of epilepsies.
Patients who do not meet criteria for epilepsy, for example those with a single seizure, should be classified as to a seizure type, but classification should stop there. The epilepsy classification is broader in scope than the seizure classification, and considers the possibility of having multiple seizure types, and incorporates information about the overall clinical picture, genetics, laboratory tests, prognoses, and comorbidities. Hence, the epilepsy classification provides additional information that is critical in guiding the patient's management.
We have illustrated the 2017 ILAE epilepsy classification in Figure 4. Epilepsies are categorized into focal, generalized, combined generalized and focal, and unknown types. To position a patient into one of these categories, the first step remains the accurate classification of the seizure type(s), and then use all the additional information available to classify into one of the epilepsy subcategories. The new group of “combined generalized and focal epilepsy” has been devised because there are epilepsy syndromes such as Dravet syndrome and Lennox–Gastaut Syndrome, in which both generalized and focal seizures often coexist.
An “epilepsy type” is a separate designation than an epilepsy syndrome, and the two should not be confused. Epilepsy syndromes refer to clusters of features such as seizure type(s), age of onset, family history, EEG and MRI findings, age-dependent attributes, seizure triggers, optimum therapy, long-term outcome and comorbidities and impact of epilepsy on the patient's quality of life. Ultimately, the identification of epilepsy and epileptic syndromes is essentially like solving a jigsaw puzzle and stands on the foundation of an accurate description and identification of seizure type(s), along with other features listed above (Fig. 5). An epilepsy syndromic diagnosis provides more sophisticated information than does an epilepsy type diagnosis. While there are many well recognized syndromes the ILAE has at present formally classified, new syndromes are regularly being added, and these might be a part or even the basis of future classifications.
zoom view
Fig. 5: Approach to epilepsy syndromic diagnosis: Solving the jigsaw puzzle.
(ASM: antiseizure medicine; EEG: electroencephalogram; MRI: magnetic resonance imaging)
 
ETIOLOGICAL CLASSIFICATION OF EPILEPSIES
The six etiologic categories defined by ILAE Task Force focus on those with management implications; they are not hierarchical and more than one etiology might coexist in an individual patient (Fig. 4).7
  1. Structural: A structural etiology can be concluded when a finding on neuroimaging is reasonably inferred to be the cause of the patient's seizures based on concordant clinical and EEG findings.23 An imaging abnormality with discordant seizure semiology and EEG findings is likely unrelated to the patient's epilepsy and would not be considered relevant when determining the etiology.
  2. Genetic: When a specific disease-causing gene variant or copy number variant, which is believed to be pathogenic for epilepsy, is documented in a person with epilepsy, a genetic etiology can be concluded. Additionally, having relevant positive family history and concordant features (seizure semiology and EEG) even without the molecular genetic result is sufficient for ascribing genetic etiology. Genetic disease-causing variants often arise de novo and may not be inherited, so a family history of epilepsy is frequently absent, despite the patient having a genetic cause for their epilepsy.24
  3. Infectious: Even though an infectious etiology can be surmised in a patient with epilepsy associated with an infectious disease, an acute infection and seizures does not constitute epilepsy as the seizures are provoked (and no epilepsy classification should be applied). Examples of infectious etiologies include neurocysticercosis, human immunodeficiency virus infection, cytomegalovirus infection, and cerebral toxoplasmosis, which are often associated with structural lesions and hence could be classified under both.
  4. Metabolic: Refers to a patient with epilepsy in whom a metabolic derangement is the cause for enduring predisposition to seizures. Someone with a transient metabolic disturbance resulting in acute symptomatic seizures would not qualify as their seizures are provoked. Many of the metabolic epilepsies are genetic in etiology, such as pyridoxine-dependent seizures and cerebral folate deficiency.
  5. Immune: Refers to epilepsies where an autoimmune disease is the cause of new-onset epilepsy. Autoimmune encephalitis and epilepsy have been linked to both neuronal cell surface and intracellular antibodies. Because of immense therapeutic implications, autoimmune etiology should be suspected and investigated in patients with recent onset seizures and epilepsies that are poorly responsive to antiseizure medicines.25
  6. Unknown: This category is reserved for patients whose etiology remains unclear, despite extensive investigations.
 
CLASSIFICATION OF NEONATAL SEIZURES AND EPILEPSIES
A detailed discussion on the new classification of neonatal seizures and epilepsies is beyond the scope of this review. Seizures are the most common neurological emergency in the neonatal period, and in contrast to those in infancy and childhood, are often provoked by an acute cause. Neonatal seizures may be electrographic only without any clinical accompaniments. Hence, neonatal seizures do not fit easily into classification schemes for seizures and epilepsies primarily developed for older children and adults. A Neonatal Seizures Task Force established by the ILAE to develop a modification of the 2017 ILAE classification of seizures and epilepsies, designed a neonatal classification framework underscoring the role of EEG in the diagnosis of neonatal seizures.16 The seizure type is determined by the predominant clinical phenomenology. As many neonatal seizures may have no overt clinical features, electrographic seizures are also included in the proposed classification. However, clinical events without an EEG correlate are not included. Because nearly all the seizures in the neonatal period have been shown to have a focal onset, a division into focal and generalized was considered to be unnecessary. Seizures can have a motor (automatisms, clonic, epileptic spasms, myoclonic, and tonic), nonmotor (autonomic and behavior arrest), or sequential presentations. The ILAE framework of neonatal seizure and epilepsy classification is depicted in Figure 6. The definitions of epileptic encephalopathy, developmental encephalopathy, and their combinations are provided in Table 1.
zoom view
Fig. 6: The International League Against Epilepsy (ILAE) 2021 classification of neonatal seizures and epilepsies.
(HIE: hypoxic-ischemic encephalopathy)
 
CRITIQUE OF THE NEW INTERNATIONAL LEAGUE AGAINST EPILEPSY CLASSIFICATIONS
Even though the new ILAE definitions and classifications have helped in clearing up some of the ambiguities of the older classifications, as listed here, there are quite a few areas the new classifications have either failed to resolve the existing inadequacies or have introduced new disagreements.26
  • Lack of objectivity of some of the newly introduced terms: Some of the new terms may lead to the wrong interpretation and cause confusion among the users of the new classifications. One such term is “awareness” which is highly subjective by definition and difficult to 8verify. The term “behavioral arrest” is also subjective and could be confused with absence seizures, especially atypical absence seizures.
  • Ambiguity with the concept of consciousness: The term “consciousness” has been replaced by “awareness” in the new classification in an attempt to simplify terminologies. However, impaired consciousness and impaired awareness are not synonymous.27 Impaired consciousness level could indicate the severity of the patients' seizures, especially with respect to activities such as driving, which the term awareness cannot provide. In a survey, more than three-fourths of the respondents agreed that the term consciousness was better than awareness, and therefore should be retained in seizure and epilepsy classifications.28 Additionally, patients with sensory-motor deficits and aphasia or amnesia may have unresponsiveness, which may be mistaken for impaired awareness, but consciousness may not be affected.
  • Inadequate coverage of preictal and postictal semiology: Preictal and postictal semiological features during the evolution and resolution of the seizures were left out in the new classification. For example, classic auras such as complex visual hallucinations, rising epigastric sensations, déjà vu, or choking sensations in the throat can all help to localize from where in the cortex the seizures are likely to be arising from.
  • Scanty emphasis on comorbidities: Comorbidities such as anxiety, depression, and cognitive and behavioral disturbances are highly prevalent in people with epilepsy, and they contribute to their poor quality of life. Formulating guidelines for the diagnosis of comorbidities would not only improve the current understanding of the pathophysiology of epilepsy, but also in the management.
  • Failure to adequately define some important terminologies: Descriptors and identifiers with regard to provoked and unprovoked seizures are inadequately defined in the new classification. Seizures that occur following acute brain insults such as central nervous system infections, cerebrovascular diseases, head injury, and metabolic derangements are referred to as provoked, whereas unprovoked seizures occur spontaneously. Emphasizing this concept would not only encourage cost-effective diagnostic evaluation, but also in preventing unnecessary long-term use of antiseizure drugs.
 
INTERNATIONAL LEAGUE AGAINST EPILEPSY POSITION PAPERS ON EPILEPSY SYNDROMES
Although epilepsy syndromes had been recognized as distinct electroclinical entities long before the first ILAE Classification of Epilepsies and Epilepsy Syndromes was proposed in 1985, there was no formally accepted ILAE classification of epilepsy syndromes. A series of ILAE position papers from the ILAE Nosology and Definitions Task Force provide definitions of epilepsy syndromes across different age spectrum.1721 A detailed discussion of these epileptic syndromes is beyond the scope of this review, nonetheless we have summarized the salient features in Table 4.
TABLE 4   Recommendations of the International League Against Epilepsy (ILAE) task force on epilepsy syndrome diagnosis.
  • Identification of epilepsy syndromes are helpful as they help to guide therapy and prognosticate17
  • For each epilepsy syndrome diagnosis, there is a well-defined electroclinical picture characterized by seizure type(s), typical age at onset, developmental course, comorbidities, possible antecedents, examination findings, electroencephalogram (EEG) findings, and other investigations (imaging, genetic, metabolic, infectious, and immunological results). There are also mandatory and exclusionary criteria, and alerts for each syndrome, as some patients may have atypical features, which require careful clinical correlation prior to making a syndrome diagnosis17
  • Just involving the same part of an epileptogenic network is not enough for classification as epilepsy syndromes17
  • The new term “etiology-specific epilepsy syndromes” has been proposed to describe syndromes in which there is a specific etiology for the epilepsy that is associated with a clearly defined, relatively uniform, and distinct clinical phenotype in most affected individuals (clinical presentation, seizure types, comorbidities, and natural history, and at times, response to specific therapies), as well as consistent EEG, neuroimaging, and/or genetic results17
  • Classification of epilepsy syndromes is on the basis of age of onset and type of epilepsy17
  • On the basis of the age of onset, there are neonatal and infantile onset, childhood onset, and variable age at onset, as well as idiopathic generalized epilepsies (IGEs)
  • A syndrome has a “variable age” of onset if it can begin both in those aged ≤18 years and in those aged ≥19 years (both pediatric and adult patients)1720
  • Epilepsy syndromes are further subdivided (in each age group) into generalized, focal, or generalized and focal, based on seizure type(s), along with a separate category for syndromes with developmental and/or epileptic encephalopathy (DEE) and syndromes with progressive neurological deterioration17
  • Epilepsy syndromes in neonates and infants are divided into two groups: Self-limited epilepsy syndromes and DEEs, with a separate category for etiology-specific syndromes17,18
  • Syndromes with onset in childhood are divided into three categories: Self-limited focal epilepsies, generalized epilepsies, and DEEs19
  • Syndromes with variable onset can be broadly divided into generalized, focal, and combined generalized and focal epilepsy syndromes. Some syndromes can be associated with developmental and/or epileptic encephalopathy in children or with progressive neurological deterioration if they begin later in life20
  • The term “genetic generalized epilepsies (GGEs)” is to be used for the broad group of epilepsies with generalized seizure types and generalized spike-wave, based on a presumed genetic etiology. They include the IGEs and others which may have developmental encephalopathy, epileptic encephalopathy, both, or neither. IGE includes four syndromes: Childhood absence epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy, and epilepsy with generalized tonic–clonic seizures alone. The second group includes syndromes such myoclonic absence epilepsy, epilepsy with eyelid myoclonia, and others21
9
 
FUTURE PERSPECTIVES
A comprehensive characterization of epilepsy requires, in addition to seizure semiology, incorporation of other dimensions involving the brain area and brain networks, cause of the seizures, associated comorbidities, and consequences of seizures. Even though the latest emphasis by ILAE on the identification and definition of epilepsy syndromes is a step in the right direction, the present three-dimensional ILAE classifications systems fall short in the multidimensional approach. A different classification system for epilepsy was proposed by Lüders et al.,29 which incorporated the clinical semiology, epileptogenic zone, etiology, and comorbidities and is referred to as the four-dimensional epilepsy classification system. Loddenkemper et al.30 recommended a five-dimensional classification system which included, in addition to the above mentioned four-dimensions, seizure burden, which impacts the quality of life, as the fifth-dimension. The rapid advances in the delineation of structural, functional, and effective brain connectivity and genomics will have tremendous impact on future classifications of seizures and epilepsies. The ultimate objective of epilepsy classification should be to individualize diagnostic and therapeutic strategies, thereby promoting the practice of precision medicine.
 
CASE SCENARIOS
We have provided three case scenarios in the Text Box 1 to illustrate the application of the new seizure and epilepsy classification systems.
 
ACKNOWLEDGMENT
The authors wish to thank Mr Magith Thampi, PhD scholar, Department of Neurology, Kasturba Medical College, Manipal, Karnataka, for his help in designing the figures.
REFERENCES
  1. Brodie MJ, Zuberi SM, Scheffer IE, et al. The 2017 ILAE classification of seizure types and the epilepsies: what do people with epilepsy and their caregivers need to know? Epileptic Disord. 2018;20:77–87.
  1. Engel J Jr; International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia. 2001;42:796–803.
  1. Arya R. Ancient Indian concepts about phenomenology, biology, and therapeutics of epilepsy. J Hist Neurosci. 2018;27:56–71.
  1. Wolf P. History of epilepsy: nosological concepts and classification. Epileptic Disord. 2014;16:261–9.
  1. Arnautova EN, Nesmeianova TN. A proposed international classification of epileptic seizures. Epilepsia. 1964;5:297–306.
  1. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1981;22:489–501.
  1. Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. Epilepsia. 1989;30:389–99.
  1. Fisher RS, van Emde Boas W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005;46:470–2.
  1. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia. 2010;51(4):676–85.
  1. Berg AT, Scheffer IE. New concepts in classification of the epilepsies: entering the 21st century. Epilepsia. 2011;52:1058–62.
  1. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475–82.
  1. Fisher RS, Cross JH, French JA, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:522–30.
  1. Fisher RS, Cross JH, D'Souza C, et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017;58:531–42.
  1. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512–21.
  1. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia. 2010;51:1069–77.
  1. Pressler RM, Cilio MR, Mizrahi EM, et al. The ILAE classification of seizures and the epilepsies: Modification for seizures in the neonate. Position paper by the ILAE Task Force on Neonatal Seizures. Epilepsia. 2021;62:615–28.
  1. Wirrell EC, Nabbout R, Scheffer IE, et al. Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1333–48.
  1. Zuberi SM, Wirrell E, Yozawitz E, et al. ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1349–97.
  1. Specchio N, Wirrell EC, Scheffer IE, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1398–442.
  1. Riney K, Bogacz A, Somerville E, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age: position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022; 63(6):1443–74.
  1. Hirsch E, French J, Scheffer IE, et al. ILAE definition of the Idiopathic Generalized Epilepsy Syndromes: Position statement by the ILAE Task Force on Nosology and Definitions. Epilepsia. 2022;63(6):1475–99.
  1. Blumenfeld H. What is a seizure network? Long-range network consequences of focal seizures. Adv Exp Med Biol. 2014;813:63–70.

  1. 11 Lapalme-Remis S, Cascino GD. Imaging for Adults with seizures and epilepsy. Continuum (Minneap Minn). 2016;22(5, Neuroimaging):1451–79.
  1. Hildebrand MS, Dahl HH, Damiano JA, et al. Recent advances in the molecular genetics of epilepsy. J Med Genet. 2013;50:271–9.
  1. Toledano M, Pittock SJ. Autoimmune Epilepsy. Semin Neurol. 2015;35:245–58.
  1. Lüders H, Akamatsu N, Amina S, et al. Critique of the 2017 epileptic seizure and epilepsy classifications. Epilepsia. 2019;60:1032–9.
  1. Blumenfeld H. Impaired consciousness in epilepsy. Lancet Neurol. 2013;11:814–26.
  1. Mathern GW, Beninsig L, Nehlig A. From the editors: Epilepsia's 2014 Operational Definition of Epilepsy Survey. Epilepsia. 2014;55:1683–7.
  1. Lüders H, Vaca GF, Akamatsu N, et al. Classification of paroxysmal events and the four-dimensional epilepsy classification system. Epileptic Disord. 2019;21:1–29.
  1. Loddenkemper T, Kellinghaus C, Wyllie E, et al. A proposal for a five-dimensional patient-oriented epilepsy classification. Epileptic Disord. 2005;7:308–16.